Abstract:

Objective To investigate the inhibitory effects of resveratrol （Res） on the growth of hormone-dependent and castration-resistant prostate cancer （PCa） and explore its mechanisms. Methods Subcutaneous xenograft models were established in nude mice using the human prostate cancer cell lines LNCaP （hormone-sensitive） and its castration-resistant derivative LNCaP-B. Thirty nude mice were randomly divided into three groups： control group， Res-treated and docetaxel. Tumor growth was recorded. Quantitative real-time polymerase chain reaction （qRT-PCR） and Western blot were performed to assess androgen receptor （AR） mRNA and protein expression levels in tumor tissues. Results Moderate- and high-dose Res significantly inhibited the growth of both LNCaP and LNCaP-B xenografts in a dose-dependent manner， with statistical significance （P < 0.05）. qRT-PCR and Western blot analyses revealed that Res markedly downregulated AR mRNA expression and protein levels compared to the control group. However， no significant pathological alterations were observed in HE-stained tumor sections. Conclusions Resveratrol suppresses the growth of hormone-dependent and castration-resistant prostate cancer by inhibiting AR expression and signaling pathway activity. These findings highlight its potential as an adjuvant therapeutic agent to androgen deprivation therapy （ADT）， providing a theoretical foundation for its clinical application in PCa treatment.

Key words: resveratrol, prostate cancer, nudemice, LNCaP cells, LNCaP-B cells